Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Somalogic Inc's Business Segments
Somalogic Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 22
Regions Reported
-
Somalogic Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Service81%
- Product15.5%
- Product and Service, Other0%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Service | $ 18 | 81% |
| Product | $ 3 | 15.5% |
| Product and Service, Other | $ 0 | 0% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue by Product & Service Category - FY
- Royalty13.5%
- Previously Constrained Royalties8.2%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Royalty | $ 13 | 13.5% |
| Previously Constrained Royalties | $ 8 | 8.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Somalogic Inc
SomaLogic Inc. is a privately held biotechnology company located in Boulder, Colorado, specializing in the development and application of protein detection technology for the advancement of healthcare and diagnostics. The company was founded in 2000 by Larry Gold, a renowned scientist and inventor of the gold standard SELEX technology, which is used for the identification of specific protein binding molecules.
The company’s proprietary SOMAscan platform is based on a modified version of DNA aptamers, which are short single-stranded DNA molecules that bind specifically to target proteins with high affinity and selectivity. The SOMAscan assay measures the levels of over 7,000 different proteins in a single serum or plasma sample, providing a comprehensive and highly sensitive “snapshot” of an individual’s health status.
SomaLogic has developed strategic partnerships with multiple organizations and institutions to apply the SOMAscan technology in different settings. The company has collaborated with the National Institutes of Health (NIH) to study biomarker discovery in a wide range of diseases, including Alzheimer’s disease, cancer, heart disease, infectious diseases, and metabolic disorders.
SomaLogic has also partnered with several pharmaceutical companies to assist in drug discovery and development, including Novartis, Bristol Myers Squibb, and Debiopharm Group. Through these partnerships, the SOMAscan technology has been used to identify potential targets for drug development, validate drug candidates, and assess drug efficacy and safety.
In addition to its research and development efforts, SomaLogic offers commercial services for healthcare and pharmaceutical companies, including biomarker discovery, drug development support, and clinical testing, among others.
Overall, SomaLogic is a leader in the field of protein detection and personalized medicine, providing innovative solutions for research and clinical diagnostics. As the company continues to expand and develop new applications for its platform technology, it has the potential to revolutionize the way we diagnose and treat disease.
The company’s proprietary SOMAscan platform is based on a modified version of DNA aptamers, which are short single-stranded DNA molecules that bind specifically to target proteins with high affinity and selectivity. The SOMAscan assay measures the levels of over 7,000 different proteins in a single serum or plasma sample, providing a comprehensive and highly sensitive “snapshot” of an individual’s health status.
SomaLogic has developed strategic partnerships with multiple organizations and institutions to apply the SOMAscan technology in different settings. The company has collaborated with the National Institutes of Health (NIH) to study biomarker discovery in a wide range of diseases, including Alzheimer’s disease, cancer, heart disease, infectious diseases, and metabolic disorders.
SomaLogic has also partnered with several pharmaceutical companies to assist in drug discovery and development, including Novartis, Bristol Myers Squibb, and Debiopharm Group. Through these partnerships, the SOMAscan technology has been used to identify potential targets for drug development, validate drug candidates, and assess drug efficacy and safety.
In addition to its research and development efforts, SomaLogic offers commercial services for healthcare and pharmaceutical companies, including biomarker discovery, drug development support, and clinical testing, among others.
Overall, SomaLogic is a leader in the field of protein detection and personalized medicine, providing innovative solutions for research and clinical diagnostics. As the company continues to expand and develop new applications for its platform technology, it has the potential to revolutionize the way we diagnose and treat disease.
SomaLogic Inc. is a pioneering biotechnology company focused on harnessing its innovative protein detection technology to address critical challenges in medical diagnostics and drug development. The companys proprietary platform enables the generation of detailed protein profiles, providing insights that span various medical applications. Here is an extensive overview of SomaLogic’s segments, products, and services.
Segments:
1. Diagnostics
SomaLogic operates in the diagnostics segment by providing advanced solutions that utilize its proprietary protein detection technology to measure and analyze a comprehensive range of proteins in blood samples. This segment addresses a diverse array of diseases, enabling clinicians to gain early diagnostic insights and monitor disease progression effectively.
- SOMAscane Assay: This flagship diagnostic test measures over 5,000 proteins from a single blood sample. It is designed for comprehensive diagnostics, providing a robust platform for detecting and identifying protein biomarkers associated with various health conditions. The SOMAscane assay supports numerous clinical applications, from early disease detection to personalized medicine approaches, allowing for adept and informed clinical decision-making.
- SomaSignale Tests: These specialized diagnostic tests focus on profiling specific proteins within the blood, aiding in the diagnosis, monitoring, and details of several diseases, including cancer, liver, and cardiovascular diseases. SomaSignale tests offer targeted insights that can significantly enhance a physicians ability to formulate effective treatment strategies.
Drug Discovery
SomaLogic leverages its protein detection and analytical capabilities within the realm of drug discovery and development. This segment entails the identification and validation of therapeutic targets critical to the development of new drugs.
- Target Identification and Validation: This service supports the pharmaceutical sector by identifying and confirming protein targets that are integral to disease mechanisms. The proprietary platform analyzes signaling molecules and establishes unique protein profiles from which potential therapeutic targets can be derived, facilitating the development of novel treatments.
- Companion Diagnostic Development: Collaborating closely with pharmaceutical companies, SomaLogic develops companion diagnostics that are essential for identifying patient populations most likely to respond favorably to specific therapies. Such collaborations enhance the efficacy and precision of therapeutic interventions, contributing to improved patient outcomes.
Products and Services:
1. SOMAscane Assay
The SOMAscane assay is a cornerstone product for SomaLogic. It is characterized by high throughput and is capable of evaluating over 5,000 proteins in a single sample. The assay serves multiple purposes:
- Research: It is instrumental in academic and clinical research for discovering new protein biomarkers associated with diseases.
- Preclinical Studies: It supports drug discovery initiatives by identifying potential drug targets and assessing therapeutic outcomes.
SomaSignale Tests
SomaSignale tests provide detailed profiling of selected proteins, delivering critical information that assists healthcare providers in diagnosing and monitoring several diseases:
- Chronic Disease Management: The tests are vital for understanding the progression of diseases such as cancer and liver dysfunction, offering insights that inform treatment adjustments.
- Personalized Treatment Plans: By connecting specific protein levels with disease states, SomaSignale tests aid clinicians in tailoring therapies to individual patient needs.
Companion Diagnostics
SomaLogics development of companion diagnostics represents a significant advancement in personalized medicine. These tests are crucial in:
- Therapeutic Targeting: By determining which patients will benefit most from a given therapy, they enhance the strategic deployment of medical treatments, thereby optimizing healthcare resources.
Research Services
SomaLogic offers an extensive range of research services that cater to both academic and industry clients:
- Protein Biomarker Discovery: Through sample analysis and protein profiling, the company aids clients in identifying biomarkers that can drive future therapeutic developments.
- Preclinical Models: SomaLogic supports drug discovery by developing preclinical models based on their protein analysis capabilities, enhancing the predictive power of research studies.
Conclusion
SomaLogic Inc. stands at the forefront of biotechnology innovation through its comprehensive suite of diagnostic and drug discovery products. By integrating advanced protein measurement techniques with sophisticated data analysis and application development, the company enhances disease diagnosis precision and fosters the development of targeted therapeutic interventions. Through its distinct segments and offerings, SomaLogic is significantly contributing to the evolution of personalized medicine and the advancement of healthcare solutions.
Segments:
1. Diagnostics
SomaLogic operates in the diagnostics segment by providing advanced solutions that utilize its proprietary protein detection technology to measure and analyze a comprehensive range of proteins in blood samples. This segment addresses a diverse array of diseases, enabling clinicians to gain early diagnostic insights and monitor disease progression effectively.
- SOMAscane Assay: This flagship diagnostic test measures over 5,000 proteins from a single blood sample. It is designed for comprehensive diagnostics, providing a robust platform for detecting and identifying protein biomarkers associated with various health conditions. The SOMAscane assay supports numerous clinical applications, from early disease detection to personalized medicine approaches, allowing for adept and informed clinical decision-making.
- SomaSignale Tests: These specialized diagnostic tests focus on profiling specific proteins within the blood, aiding in the diagnosis, monitoring, and details of several diseases, including cancer, liver, and cardiovascular diseases. SomaSignale tests offer targeted insights that can significantly enhance a physicians ability to formulate effective treatment strategies.
Drug Discovery
SomaLogic leverages its protein detection and analytical capabilities within the realm of drug discovery and development. This segment entails the identification and validation of therapeutic targets critical to the development of new drugs.
- Target Identification and Validation: This service supports the pharmaceutical sector by identifying and confirming protein targets that are integral to disease mechanisms. The proprietary platform analyzes signaling molecules and establishes unique protein profiles from which potential therapeutic targets can be derived, facilitating the development of novel treatments.
- Companion Diagnostic Development: Collaborating closely with pharmaceutical companies, SomaLogic develops companion diagnostics that are essential for identifying patient populations most likely to respond favorably to specific therapies. Such collaborations enhance the efficacy and precision of therapeutic interventions, contributing to improved patient outcomes.
Products and Services:
1. SOMAscane Assay
The SOMAscane assay is a cornerstone product for SomaLogic. It is characterized by high throughput and is capable of evaluating over 5,000 proteins in a single sample. The assay serves multiple purposes:
- Research: It is instrumental in academic and clinical research for discovering new protein biomarkers associated with diseases.
- Preclinical Studies: It supports drug discovery initiatives by identifying potential drug targets and assessing therapeutic outcomes.
SomaSignale Tests
SomaSignale tests provide detailed profiling of selected proteins, delivering critical information that assists healthcare providers in diagnosing and monitoring several diseases:
- Chronic Disease Management: The tests are vital for understanding the progression of diseases such as cancer and liver dysfunction, offering insights that inform treatment adjustments.
- Personalized Treatment Plans: By connecting specific protein levels with disease states, SomaSignale tests aid clinicians in tailoring therapies to individual patient needs.
Companion Diagnostics
SomaLogics development of companion diagnostics represents a significant advancement in personalized medicine. These tests are crucial in:
- Therapeutic Targeting: By determining which patients will benefit most from a given therapy, they enhance the strategic deployment of medical treatments, thereby optimizing healthcare resources.
Research Services
SomaLogic offers an extensive range of research services that cater to both academic and industry clients:
- Protein Biomarker Discovery: Through sample analysis and protein profiling, the company aids clients in identifying biomarkers that can drive future therapeutic developments.
- Preclinical Models: SomaLogic supports drug discovery by developing preclinical models based on their protein analysis capabilities, enhancing the predictive power of research studies.
Conclusion
SomaLogic Inc. stands at the forefront of biotechnology innovation through its comprehensive suite of diagnostic and drug discovery products. By integrating advanced protein measurement techniques with sophisticated data analysis and application development, the company enhances disease diagnosis precision and fosters the development of targeted therapeutic interventions. Through its distinct segments and offerings, SomaLogic is significantly contributing to the evolution of personalized medicine and the advancement of healthcare solutions.